Baird Medical Establishes U.S. Manufacturing Base to Accelerate Global Expansion and Future R&D

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) announced on Dec. 17, 2025 the establishment of a dedicated U.S. manufacturing base to support its global expansion.

The company said it partnered with California-based MPS Medical to create a centralized production hub in North America, shifting from an exporter model toward a comprehensive global medical technology provider. The facility is described as supplying Baird Medical's proprietary Microwave Ablation technologies to global markets and improving quality and supply chain efficiency. Recent commercial growth noted includes market penetrations in Indonesia and Malaysia.

Positive

• Established U.S. manufacturing base in North America
• Partnership formed with California-based MPS Medical
• Centralized production hub to supply global markets
• Aimed to improve quality control and supply chain efficiency
• Noted recent market penetration in Indonesia and Malaysia

Negative

• None.

Market Reality Check

$1.30 Last Close

Volume Volume 74,768 vs 20-day average 142,852 (relative volume 0.52x) ahead of this news. low

Technical Price $1.37 is below 200-day MA at $3.36 and 89.04% below the 52-week high.

Peers on Argus

BDMD was up 1.48% pre-news while key peers were mixed: ICAD up 3.48%, APYX down 3.88%, ICCM down 3.44%, NSPR down 1.02%, XTNT down 5.22%, suggesting a stock-specific setup rather than a broad sector move.

Common Catalyst Peer ICCM had news tied to FDA clearance and North American sales, reflecting ongoing innovation and commercialization activity across minimally invasive oncology devices.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 08	Training initiative	Positive	-4.9%	Advanced MWA training for Arizona surgeon with live procedures and certification.
Dec 03	Leadership change	Positive	+11.1%	Appointment of experienced U.S. CEO to lead commercial expansion for MWA platform.
Nov 03	Market entry	Positive	-9.2%	First successful microwave bone ablation marking entry into Egyptian market.
Oct 27	Reimbursement milestone	Positive	+2.1%	Medicare-reimbursed thyroid MWA procedures at a New York endocrinology practice.
Oct 23	Clinical milestone	Positive	-5.9%	First successful liver tumor MWA procedure in Bangladesh demonstrating regional adoption.

Pattern Detected

Operational and expansion news has often been positive in tone but produced mixed to negative next-day moves, with several clinical/commercial milestones followed by price declines.

Recent Company History

Over the last few months, Baird Medical has highlighted multiple global expansion and adoption milestones. These include successful liver and bone tumor ablations in Bangladesh and Egypt (Oct 23, Nov 3), Medicare-reimbursed thyroid MWA procedures in New York (Oct 27), a U.S. CEO appointment with strong M&A/IPO background (Dec 3), and advanced MWA training in Arizona (Dec 8). Today’s U.S. manufacturing base announcement continues this theme of building global clinical presence and commercial infrastructure.

Market Pulse Summary

This announcement describes Baird Medical’s establishment of a U.S. manufacturing base and partnership with MPS Medical to support global distribution of its MWA technology. It follows recent milestones in new geographies and U.S. clinical adoption, reinforcing a strategy of international expansion and infrastructure building. Investors may watch for concrete data on production capacity, geographic revenue mix, and further U.S. commercialization updates to assess execution of this growth strategy.

Key Terms

microwave ablation (MWA) medical

"a market leader in Microwave Ablation (MWA) technology, today announced"

Microwave ablation (MWA) is a minimally invasive medical procedure that uses focused microwave energy to heat and destroy unwanted tissue, such as tumors or lesions, without open surgery. Think of it like using a tiny, precise microwave oven inside the body to remove a problem area; for investors, MWA matters because its effectiveness, safety, costs, and adoption influence demand for related devices, hospital procedures, reimbursement and potential market growth.

AI-generated analysis. Not financial advice.

NEW YORK, Dec. 17, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in Microwave Ablation (MWA) technology, today announced the establishment of a dedicated manufacturing base in the United States. This development marks a pivotal step in Baird Medical's transition from a specialized exporter to a comprehensive global medical technology enterprise.

The decision to anchor production in North America is driven by the Company's rapid commercial success across over a dozen countries, including recent significant market penetrations in Indonesia and Malaysia. To support this international footprint, Baird Medical has partnered with California-based MPS Medical to create a centralized production hub. This facility is designed to supply Baird Medical's advanced proprietary technologies to global markets, ensuring the highest standards of quality and supply chain efficiency for its expanding client base.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

About MPS Medical

MPS Medical, Inc. is a privately held medical device company with offices and manufacturing facilities Southern California. Since its founding 30 years ago, MPS has been committed to providing exceptional medical device manufacturing services and high-quality diagnostic products to help improve healthcare and patient outcomes throughout the United States.

MPS was founded as a manufacturer and supplier of FDA-approved medical devices and now serves as a U.S. hub for the licensing, manufacturing, and distribution of high-quality, foreign-developed medical technologies. MPS manufacturing facility is over 30,000 sq ft, including a 3,000 sq ft class 8 cleanroom and an 18,000 sq ft temperature-controlled warehouse. The facility is both FDA registered and ISO certified. MPS's is certified to ISO 13485 standards, US FDA 21 CFR Part 820 Quality System regulations and ISO 14971 Medical Device, Risk Management standards.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-establishes-us-manufacturing-base-to-accelerate-global-expansion-and-future-rd-302644327.html

SOURCE BDMD

FAQ

What did Baird Medical (BDMD) announce on December 17, 2025?

Baird Medical announced a new U.S. manufacturing base and a partnership with MPS Medical to create a centralized production hub.

How will the new BDMD U.S. facility affect supply chain and product quality?

The company said the facility is designed to improve quality control and supply chain efficiency for global distribution.

Who is Baird Medical partnering with for its U.S. manufacturing base?

Baird Medical partnered with California-based MPS Medical to establish the centralized production hub.

Does the BDMD announcement mention specific market growth supporting the move?

Yes; the company cited rapid commercial success with recent significant penetrations into Indonesia and Malaysia.

Will the new BDMD U.S. hub supply products to international markets?

Yes; the hub is described as a centralized production facility intended to supply Baird Medical's technologies to global markets.